Latest News

Wet AMD gains a new FDA-approved therapy as retina, glaucoma, and dry eye pipelines surge—plus AI, devices, and workforce trends reshaping care.

In part 2 of a 2-part article, Arun C. Gulani, MD, walks through the 4 patient types of the Gulani classification of refractive lens exchange, from primary vision enhancement to staged vision engineering, and explains why outcomes depend on treating the eye as a complete optical system rather than on the implant alone.

The annual Best Hospitals report from US News & World Report compares more than 4500 hospitals across 14 specialties and 22 procedures and conditions.

The first half of 2026 turned on inherited pediatric eye disease, with 2 gene therapy programs advancing toward registration and a high-profile complete response letter in a childhood-onset optic neuropathy.

The FDA has cleared an IND for RAG-1C, a first-in-class saRNA therapy targeting proliferative vitreoretinopathy.

Home OCT now gives us the next dimension: time.

Retina specialists Baruch D. Kuppermann, MD, PhD, and Firas M. Rahhal, MD, discuss the significance of bevacizumab-vikg's approval for wet AMD and its impact on physicians and patients.

Seven-year Vestrum data: anti-VEGF gaps hit 40% of patients with wet AMD by year 1, worsening vision.

An investigational drug has shown positive activity against metastatic uveal melanoma in a phase 1 study.

Findings highlight the need for routine bilateral endothelial assessment in herpetic eye disease

When patients fall outside pivotal clinical trial criteria, retina specialists factor in real-world judgment to guide treatment.

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.

Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.